BOLD CLINICAL TRIALS
One DES head-to-head trial.
Built for sustained drug release and efficient drug transfer.
Exceptional outcomes vs. Zilver™ PTX™
Eluvia DES demonstrated a statistically significant difference in primary patency versus Zilver PTX3 and achieved the highest primary patency reported in any SFA DE Pivotal Trial at 1-Year4.
**Log-rank p-value compares the entire K-M curves from time zero to full 1-Year follow-up window.
1. 92.1% K-M Primary Patency. 1-Year Results published in The Lancet. https://doi.org/10.1016/S0140-6736(18)32262-1.
2. Based on drug dose data from Eluvia DES, Lutonix 018 DCB, Lutonix 035 DCB, Stellarex 035 DCB and Ranger DCB Instructions for Use.
3. Kaplan-Meier Primary Patency Estimate through 1-Year (including follow-up window) was statistically significant with a p-value of 0.0094.
4. Based on 1-Year Kaplan-Meier estimates reported for IMPERIAL, RANGER II SFA, IN.PACT SFA, ILLUMENATE, LEVANT II and Primary Randomization for Zilver PTX RCT.
RESTENOSIS REPLACEMENT PROGRAM
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.